Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073465 | 0.81 | FGFR1 (0.33) | FGFR1SRC | |
| SCHEMBL6073576 | 0.81 | FGFR1 (0.38) | FGFR1SRC | |
| SCHEMBL27103130 | 0.74 | FGFR1 (0.61) | FGFR1HTTKMT2ASRC | |
| SCHEMBL16071811 | 0.73 | FGFR1 (0.68) | FGFR1 | |
| SCHEMBL6073507 | 0.72 | NOS3 (0.31) | — | |
| SCHEMBL24457853 | 0.71 | FGFR1 (0.40) | FGFR1HTTKMT2ASRC | |
| SCHEMBL29742257 | 0.71 | FGFR1 (0.40) | FGFR1HTTKMT2ASRC | |
| SCHEMBL6073344 | 0.71 | FGFR1 (0.40) | FGFR1HTTKMT2ASRC | |
| SCHEMBL20743143 | 0.71 | HTT (0.42) | FGFR1HTTKMT2A | |
| SCHEMBL15280147 | 0.67 | PARG (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053070-B2 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | BOOTH RICHARD JOHN (US) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073668-A1 | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors | CDK9, CDK19, CDK3 | FGFR1 280/4885HTT 4799/4885KMT2A 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.